DK1105122T3 - Pharmaceutical compositions containing lipase inhibitors - Google Patents

Pharmaceutical compositions containing lipase inhibitors

Info

Publication number
DK1105122T3
DK1105122T3 DK99940127T DK99940127T DK1105122T3 DK 1105122 T3 DK1105122 T3 DK 1105122T3 DK 99940127 T DK99940127 T DK 99940127T DK 99940127 T DK99940127 T DK 99940127T DK 1105122 T3 DK1105122 T3 DK 1105122T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
compositions containing
lipase inhibitors
containing lipase
inhibitors
Prior art date
Application number
DK99940127T
Other languages
English (en)
Inventor
Hans-Peter Maerki
Manuela Hug
Marcel Meier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1105122T3 publication Critical patent/DK1105122T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • General Preparation And Processing Of Foods (AREA)
DK99940127T 1998-08-14 1999-08-02 Pharmaceutical compositions containing lipase inhibitors DK1105122T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98115311 1998-08-14
EP99109516 1999-05-12
EP99940127A EP1105122B1 (en) 1998-08-14 1999-08-02 Pharmaceutical compositions containing lipase inhibitors

Publications (1)

Publication Number Publication Date
DK1105122T3 true DK1105122T3 (da) 2005-08-08

Family

ID=26149537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99940127T DK1105122T3 (da) 1998-08-14 1999-08-02 Pharmaceutical compositions containing lipase inhibitors

Country Status (19)

Country Link
US (1) US6358522B1 (da)
EP (1) EP1105122B1 (da)
JP (1) JP3774118B2 (da)
KR (1) KR20010079635A (da)
CN (1) CN1170534C (da)
AR (1) AR035001A1 (da)
AT (1) ATE293970T1 (da)
AU (1) AU761351B2 (da)
BR (1) BR9912980B1 (da)
CA (1) CA2340056C (da)
CO (1) CO5130009A1 (da)
DE (1) DE69924999T2 (da)
DK (1) DK1105122T3 (da)
ES (1) ES2242413T3 (da)
MA (1) MA26671A1 (da)
PE (1) PE20000953A1 (da)
PT (1) PT1105122E (da)
TR (1) TR200100471T2 (da)
WO (1) WO2000009122A1 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
AU745697B2 (en) 1998-09-08 2002-03-28 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
ES2269441T3 (es) * 2000-06-27 2007-04-01 F. Hoffmann-La Roche Ag Metodo para la preparacion de una composicion.
ATE293477T1 (de) 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
KR100572785B1 (ko) 2000-07-28 2006-04-19 에프. 호프만-라 로슈 아게 신규한 약학 조성물
CA2417607C (en) 2000-08-09 2008-01-29 Christine Feinle Lipase inhibitors for the treatment of dyspepsia
WO2002044152A1 (en) 2000-10-16 2002-06-06 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-ht2 receptor ligands
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
BR0116605A (pt) 2000-12-27 2003-09-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2002338896B2 (en) 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
PL372295A1 (en) 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
BR0308108A (pt) 2002-02-28 2004-12-07 Hoffmann La Roche Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
PL216022B1 (pl) 2002-04-26 2014-02-28 Hoffmann La Roche Kompozycja farmaceutyczna, sposób jej wytwarzania i jej zastosowanie, zestaw do leczenia otylosci, inhibitor lipazy w postaci orlistatu i glukomannan lub konjac, zastosowanie inhibitora lipazy w postaci orlistatu oraz zastosowanie glukomannanu lub konjacu
CA2489251A1 (en) 2002-07-05 2004-01-15 F. Hoffmann-La Roche Ag Quinazoline derivatives
AU2003253364B2 (en) 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
WO2004024726A1 (en) 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
DE60323130D1 (de) 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CN100393718C (zh) 2003-08-12 2008-06-11 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的噻唑衍生物
CA2533463A1 (en) 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag 2-amino-5-benzoylthiazole npy antagonists
CA2609634C (en) 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
JP5044398B2 (ja) 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
DE602006006712D1 (de) 2005-08-18 2009-06-18 Hoffmann La Roche Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ATE507222T1 (de) 2005-11-30 2011-05-15 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
CA2630270A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
DE602006020482D1 (de) 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
CN101326187A (zh) 2005-12-15 2008-12-17 霍夫曼-拉罗奇有限公司 吡咯并[2,3-c]吡啶衍生物
BRPI0619985A2 (pt) 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
EP2032554A1 (en) 2006-05-30 2009-03-11 F. Hoffmann-Roche AG Piperidinyl pyrimidine derivatives
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
CA2686257C (en) * 2007-05-16 2013-07-02 Buckman Laboratories International, Inc. Methods to control organic contaminants in fibers
WO2009013195A1 (en) 2007-07-25 2009-01-29 F. Hoffmann-La Roche Ag Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
BR112018075415A2 (pt) * 2016-06-17 2019-03-12 The Procter & Gamble Company composição mastigável macia compreendendo plantago
CN112220831A (zh) * 2020-08-07 2021-01-15 天津盛实百草中药科技有限公司 圆苞车前子壳粉在缓解奥利司他副作用中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JPH09252746A (ja) * 1996-03-22 1997-09-30 Nippon Kankyo Yakuhin Kk 栄養補助食品
JP4202439B2 (ja) * 1996-10-01 2008-12-24 江崎グリコ株式会社 フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions

Also Published As

Publication number Publication date
CA2340056C (en) 2007-01-09
DE69924999T2 (de) 2006-05-04
PE20000953A1 (es) 2000-09-26
AR035001A1 (es) 2004-04-14
BR9912980A (pt) 2001-05-08
KR20010079635A (ko) 2001-08-22
AU5418599A (en) 2000-03-06
AU761351B2 (en) 2003-06-05
ES2242413T3 (es) 2005-11-01
CA2340056A1 (en) 2000-02-24
JP2002522491A (ja) 2002-07-23
BR9912980B1 (pt) 2013-10-22
EP1105122A1 (en) 2001-06-13
CN1312713A (zh) 2001-09-12
ATE293970T1 (de) 2005-05-15
PT1105122E (pt) 2005-08-31
CO5130009A1 (es) 2002-02-27
EP1105122B1 (en) 2005-04-27
TR200100471T2 (tr) 2001-07-23
DE69924999D1 (de) 2005-06-02
MA26671A1 (fr) 2004-12-20
WO2000009122A1 (en) 2000-02-24
CN1170534C (zh) 2004-10-13
US6358522B1 (en) 2002-03-19
JP3774118B2 (ja) 2006-05-10

Similar Documents

Publication Publication Date Title
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
PT1105123E (pt) Composicoes farmaceuticas contendo inibidores da lipase e quitosano
EE200000488A (et) Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid
IS5046A (is) Lyfjasamsetningar
PT1066027E (pt) Composicao farmaceutica de topiramato
ID27415A (id) Komposisi farmaseutik
MA26818A1 (fr) Formulations contenant des inhibiteurs de lipase
DK1052974T3 (da) Farmaceutisk sammensætning indeholdende epothilon
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
DE69832516D1 (de) Isoflavon-enthaltende zusammensetzungen
DE69836106D1 (de) Stanolester enthaltende Zusammensetzungen
ID18352A (id) Komposisi-komposisi farmasi
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
ID29262A (id) Komposisi farmasi
ID27201A (id) Komposisi farmasi
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
EE9800400A (et) Diklofenaaki sisaldavad farmatseutilised kompositsioonid
IS5184A (is) Lyfjasamsetningar
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
PT941100E (pt) Composicoes farmaceuticas
ID25857A (id) Komposisi farmasi
EE200100281A (et) Analgeetiline ravimkoostis
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused